ScreenerHero

EVGN Evogene Ltd.

NAS · US · Healthcare · Biotechnology · evogene.com
0.4106USD-3.09%Mkt Cap: 6.49M $P/E: —

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Ap…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.49M USD
Enterprise Value7.58M USD
Revenue (TTM)1.66M USD
Gross Profit-241.00K USD
Net Income (TTM)-8.48M USD
Revenue/Share0.17 USD
Last Price0.4106 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.71
PEG—
EV/EBITDA-0.55
EV/Revenue4.57
P/S4.04
P/B-1.74
EPS (TTM)-1.55
EPS (Forward)-0.60
52W Range
0.35225% of range1.500
52W High1.500 USD
52W Low0.3522 USD
Profitability
Gross Margin-6.25%
Oper. Margin-606.63%
EBITDA Margin0.00%
Profit Margin-220.22%
ROE10347.56%
ROA-42.33%
Growth
Revenue Growth-60.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.50M USD
CapEx (TTM)135.00K USD
FCF Margin-119.34%
FCF Yield-30.48%
Net Debt-7.21M USD
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity-26.80
Current Ratio3.57
Quick Ratio3.23
Book Value/Sh-0.24 USD
Cash/Share0.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 25, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.150 USD
Upside (mean)+423.6%
Target Range2.150 USD – 2.150 USD
# Analysts1
Ownership
Shares Out.15.80M
Float12.38M
Insiders27.86%
Institutions6.36%
Short Interest
Short Ratio0.2d
Short % Float0.36%
Short % Out.0.36%
Shares Short56.81K
Short (prev mo.)232.08K
Technical
SMA 500.5226 (-21.4%)
SMA 2000.7250 (-43.4%)
Beta0.72
S&P 52W Chg16.45%
Avg Vol (30d)1.46M
Avg Vol (10d)7.31M
Technical Indicators
RSI (14)40.6
MACD-0.0337
MACD Signal-0.0337
MACD Hist.+0.0000
BB Upper0.5335 USD
BB Middle0.4499 USD
BB Lower0.3663 USD
BB Width37.16%
ATR (14)0.0565 USD
Vol Ratio (20d)0.04x